David Rubin to Indans
This is a "connection" page, showing publications David Rubin has written about Indans.
Connection Strength
3.918
-
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis. Inflamm Bowel Dis. 2026 May 01; 32(5):954-962.
Score: 0.923
-
Ozanimod-exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histological Changes. J Crohns Colitis. 2024 Apr 23; 18(4):638-641.
Score: 0.802
-
Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center. Dig Dis Sci. 2024 Feb; 69(2):579-587.
Score: 0.782
-
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age. Inflamm Bowel Dis. 2026 Mar 01; 32(3):512-525.
Score: 0.228
-
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid. Inflamm Bowel Dis. 2026 Jan 01; 32(1):77-86.
Score: 0.226
-
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial. Am J Gastroenterol. 2025 Oct 01; 120(10):2339-2349.
Score: 0.211
-
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. J Crohns Colitis. 2024 Feb 26; 18(2):264-274.
Score: 0.198
-
Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis. J Crohns Colitis. 2023 Dec 30; 17(12):2012-2025.
Score: 0.196
-
Hypertensive Emergency After Initiating Ozanimod: A Case Report. Inflamm Bowel Dis. 2022 08 01; 28(8):e114-e115.
Score: 0.178
-
Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2023 08; 21(9):2407-2409.e2.
Score: 0.174